Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Valneva SE (VLA.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
10.11+0.10 (+1.00%)
At close: 05:35PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.01
Open9.94
Bid0.00 x 0
Ask0.00 x 0
Day's Range9.86 - 10.19
52 Week Range7.26 - 29.70
Volume320,967
Avg. Volume859,498
Market Cap1.185B
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for VLA.PA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Benzinga

      Valneva Cuts FY22 COVID-19 Vaccine Sales Outlook, Needs Funding To Invest In Next-Gen COVID-19 Shot

      Valneva SE (NASDAQ: VALN) cut its FY22 revenue outlook citing lower demand for its anti-COVID shot from European Union member states. In 1H FY22, the company generated €3.8 million from its first COVID-19 vaccine sales. In light of the reduced order volume from the EU Member States, Valneva has suspended manufacturing of the vaccine and recognized write-downs of €100.6 million relating to existing inventory acquired to produce and supply volumes under the original European agreement. Valneva is

    • Reuters

      Valneva cuts full-year outlook on lower COVID-19 vaccine sales

      The European Commission in July slashed its order for VLA2001 to just 1.25 million doses from a previously targeted 60 million, pointing to European countries being well supplied with other vaccines and a slowdown in vaccination programmes. In February, Valneva had said it expected 350-500 million euros in COVID-19 vaccine sales. In the six months to June, the shot's sales brought in 3.8 million euros and the firm recognised writedowns of 100.6 million linked to the production inventory it bought to meet the initial purchase agreement with the European Commission, and subsequent halt of production.

    • GlobeNewswire

      Valneva Reports H1 2022 Results and Provides Corporate Updates

      Excellent progress on late-stage clinical programs Lyme Disease Vaccine Candidate VLA15 Phase 3 study initiated in August 20221Further positive Phase 2 results reported, including first pediatric data2 Single-Shot Chikungunya Vaccine Candidate VLA1553 Initiation of rolling submission for Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) imminentFinal positive pivotal Phase 3 results reported3Final positive lot-to-lot consistency Phase 3 results reported4 Four m

    Advertisement
    Advertisement